Case Studies & Whitepapers2025-02-10
Efficacy and Safety - Guidelines for Clinical In-use Stability Studies of ADCs Download
Antibody-drug
conjugates (ADCs) consist of three parts: antibody, linker, and payload. This
special combination enables ADCs to selectively target tumor cells and release
cytotoxic drugs, but they face many stability challenges during manufacture,
storage, and clinical use. In this paper, the drug product development team at Porton
(hereinafter referred to as "we") discusses the necessary clinical
in-use stability studies for ADCs.
At
present, the 16 ADCs currently on the market employ intr
Read more
News
More
Case Studies & Whitepapers2025-03-13
Facilitating PROTAC Drugs Development with Innovative Processes
The PROTAC technology, through an innovative mechanism of "degradation rather than inhibition," provides a new pathway for targeting traditionally undruggable proteins and addressing resistance issues.
Case Studies & Whitepapers2025-01-06
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
